Chugai & Roche vs. Celltrion: Dismissed Appeal in Anti-IL-6 Antibody Patent Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Chugai Pharmaceutical Co., Ltd. et al. v. Celltrion, Inc. |
| Case Number | 24-1111 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District Court / PTAB |
| Duration | Nov 2023 – Mar 2024 125 Days |
| Outcome | Appeal Dismissed (Unopposed) |
| Patents at Issue | |
| Accused Products | Subcutaneously Administered Anti-IL-6 Receptor Antibodies (Biosimilar Tocilizumab) |
Case Overview
The Parties
⚖️ Plaintiff
Chugai Pharmaceutical, Hoffmann-La Roche, and Genentech collectively represent one of the most formidable IP portfolios in the antibody therapeutics space.
🛡️ Defendant
A prominent South Korean biosimilar developer known for its challenges to originator biologics and consistent presence in biosimilar patent litigation.
Patents at Issue
This dispute centered on two U.S. patents protecting formulation and administration innovations in the anti-IL-6 receptor antibody field, a therapeutic class used in autoimmune conditions:
- • US 10,874,677 — Subcutaneously administered anti-IL-6 receptor antibody compositions (associated with tocilizumab)
- • US 8,580,264 — Earlier foundational patent in the same antibody technology family
Developing a biologic product?
Check if your formulation or administration route might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit **dismissed the appeal** on March 6, 2024, pursuant to an unopposed motion filed by the appellants (Chugai, Hoffmann-La Roche, and Genentech). The court ordered each side to bear its own costs. No damages were awarded, no injunctive relief was issued, and no substantive merits ruling was rendered. The case is now **closed**.
Key Legal Issues
The dismissal was **unopposed** under Federal Rule of Appellate Procedure 42(b)(2), meaning Celltrion did not contest the appellants’ motion to withdraw. This outcome pattern—a voluntary appellate dismissal with symmetric cost allocation—typically signals an out-of-court settlement, strategic withdrawal by plaintiffs, or mootness. The 125-day lifecycle from filing to dismissal is notably brief, suggesting a negotiated resolution occurred outside public record.
Freedom to Operate (FTO) Analysis for Biologics
This case highlights critical FTO risks in biologic drug development. Choose your next step:
📋 Understand Biologics IP Trends
Learn about the specific risks and implications from this and similar biologic litigations.
- View all 2 patents in this specific dispute
- See which companies are most active in anti-IL-6 IP
- Understand formulation claim construction patterns
🔍 Check My Biologic Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking biologic patents
- Get actionable risk assessment report
High Risk Area
Subcutaneous Formulation IP
2 Patents at Issue
In this anti-IL-6 antibody case
FTO Analysis Crucial
For all biologic product development
✅ Key Takeaways
Voluntary Federal Circuit dismissals under FRAP 42(b)(2) are strategically valuable tools to avoid adverse appellate precedent while preserving portfolio integrity.
Search related case law →Multi-plaintiff originator coalitions (manufacturer + parent + subsidiary) are increasingly common in biologic patent enforcement.
Explore competitor strategies →The ‘677 and ‘264 patent family illustrates effective continuation-based portfolio layering for extending formulation protection.
Analyze patent family trees →Frequently Asked Questions
U.S. Patent Nos. 10,874,677 and 8,580,264, covering subcutaneously administered anti-IL-6 receptor antibody formulations, were the patents at issue in this Federal Circuit appeal.
The appellants (Chugai, Hoffmann-La Roche, and Genentech) filed an unopposed motion to dismiss under FRAP Rule 42(b)(2). The Federal Circuit granted the motion on March 6, 2024, with no substantive merits ruling.
While no precedent was set, the case signals continued enforcement activity around biologic formulation patents and suggests that appellate-level settlements may be an increasingly preferred resolution pathway in this space.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit – Case 24-1111
- Cornell Legal Information Institute – FRAP Rule 42(b)(2)
- U.S. Patent and Trademark Office – Patent Full-Text Database
- FDA Biosimilar Product Information – Tocilizumab
- PatSnap – IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.